GRAIL, LLC, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. GRAIL, LLC was formerly known as PSC15, Inc. and changed its name to GRAIL, LLC in January 2016. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, LLC operates as a subsidiary of Illumina, Inc.